Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Sales (2020 - 2023)

Gain Therapeutics (GANX) has 4 years of Return on Sales data on record, last reported at 408.79% in Q4 2023.

  • For Q4 2023, Return on Sales fell 40701.0% year-over-year to 408.79%; the TTM value through Dec 2023 reached 408.79%, down 40701.0%, while the annual FY2023 figure was 408.79%, 40691.0% down from the prior year.
  • Return on Sales reached 408.79% in Q4 2023 per GANX's latest filing, down from 88.37% in the prior quarter.
  • Across five years, Return on Sales topped out at 360.87% in Q4 2021 and bottomed at 465.07% in Q1 2021.
  • Average Return on Sales over 4 years is 90.78%, with a median of 85.36% recorded in 2020.
  • Peak YoY movement for Return on Sales: soared 39235bps in 2022, then tumbled -40701bps in 2023.
  • A 4-year view of Return on Sales shows it stood at 141.49% in 2020, then soared by 155bps to 360.87% in 2021, then tumbled by -100bps to 1.78% in 2022, then plummeted by -22898bps to 408.79% in 2023.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 408.79% in Q4 2023, 88.37% in Q3 2023, and 85.47% in Q2 2023.